Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

137 recalls, newest first

Class II · Moderate risk

Tadalafil Tablets

Incorrect Product Formulation: An incorrect grade of Crospovidone was used to manufacture the product.

Terminated cGMP deviation Sun Pharmaceutical Industries INC NDC 16714-077-01 D-0231-2022
Class II · Moderate risk

Tadalafil Tablets

Incorrect Product Formulation: An incorrect grade of Crospovidone was used to manufacture the product.

Terminated cGMP deviation Sun Pharmaceutical Industries INC NDC 16714-075-01 D-0230-2022
Class II · Moderate risk

Omeprazole Delayed-Release Capsules

CGMP Deviations: Customer complaint for the presence of a staple co-mingled with capsules within the bottle.

Terminated cGMP deviation Dr. Reddy's Laboratories, Inc. NDC 70000-0232-1 D-0026-2022
Class II · Moderate risk

Ethosuximide Oral Solution USP 250 mg/5 mL

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Terminated cGMP deviation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-0670-16 D-0723-2021
Class II · Moderate risk

Nystatin Oral Suspension

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Terminated cGMP deviation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-0868-16 D-0721-2021

Recalls by year